Labcorp sets new medium-term growth targets and reaffirms its annual outlook

Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance management is seeking over several years, rather than an immediate upgrade to the current-year earnings forecast.

The strategy emphasizes specialty testing in areas including oncology, neurology, autoimmune conditions and women’s health, alongside deeper relationships with health systems and pharmaceutical companies. Personalized health is another stated growth priority. The targets give investors a clearer benchmark for assessing the company’s strategic execution, but remain forward-looking goals dependent on demand, investment and operating delivery. The announcement does not establish that each individual year will necessarily fall within the stated medium-term growth ranges.

Sources:

• Labcorp — financial targets, PR Newswire